Cardiovascular Drugs Practice Questions

Q: Which of the following is not a first-line antihypertensive medication?

Atenolol. The correct answer is **Atenolol**. According to current clinical guidelines (JNC 8 and AHA/ACC), **Beta-blockers** are no longer considered first-line agents for the management of primary hypertension in the absence of specific compelling indications (like post-MI or heart failure) [1, 2]. **Why Atenolol is the correct answer:** Clinical trials (such as the ASCOT-BPLA) demonstrated that Beta-blockers, particularly Atenolol, are less effective than other classes in preventing stroke and cardiovascular mortality [2]. They are also associated with an increased risk of new-onset diabetes and are less effective at reducing central aortic pressure compared to peripheral blood pressure. **Why the other options are incorrect:** * **Enalapril (ACE Inhibitor):** ACE inhibitors are first-line agents, especially beneficial in patients with diabetes or chronic kidney disease due to their renoprotective effects. * **Hydrochlorothiazide (Thiazide Diuretic):** Thiazides have long been a cornerstone of first-line therapy, proven to reduce cardiovascular morbidity and mortality effectively [3]. * **Amlodipine (Calcium Channel Blocker):** Dihydropyridine CCBs are highly effective first-line agents, particularly recommended for elderly patients and those of African descent. **High-Yield Clinical Pearls for NEET-PG:** * **First-line ABCD:** **A**CEIs/ARBs, **B**-blockers (only if compelling indications), **C**CBs, and **D**iuretics. * **Compelling Indications for Beta-blockers:** Stable angina, post-Myocardial Infarction, and Heart Failure with reduced Ejection Fraction (HFrEF) [2]. * **Side Effect Note:** Avoid Thiazides in patients with gout (hyperuricemia) and ACEIs in pregnancy (teratogenic).

Q: All of the following drugs are useful in detrusor instability except?

Duloxetine. **Explanation:** The question asks for the drug NOT used in **detrusor instability** (also known as **Overactive Bladder - OAB** or **Urge Incontinence**). **1. Why Duloxetine is the Correct Answer:** Duloxetine is a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) [4]. It is used in the management of **Stress Urinary Incontinence (SUI)**, not urge incontinence. It works by increasing the tone of the external urethral sphincter via stimulation of Onuf’s nucleus in the sacral spinal cord. In detrusor instability, the problem is an overactive bladder muscle; Duloxetine does not relax the detrusor. **2. Analysis of Incorrect Options:** * **Solifenacin & Tolterodine:** These are **M3-selective muscarinic antagonists** [1]. Since bladder contraction is mediated by M3 receptors, these drugs are the first-line pharmacological treatment for detrusor instability as they promote bladder relaxation and increase capacity [1], [2]. * **Flavoxate:** This is a tertiary amine with **antispasmodic** properties [3]. It exerts a direct relaxant effect on the smooth muscle of the urinary tract and is indicated for symptomatic relief of bladder spasms [3]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for OAB:** Oxybutynin (non-selective) or Darifenacin/Solifenacin (M3 selective) [2]. * **Mirabegron:** A **Beta-3 (β3) agonist** used for OAB; it relaxes the detrusor muscle during the storage phase. * **Stress Incontinence:** Characterized by leakage during coughing/sneezing. Treatment includes pelvic floor exercises (Kegel's) and Duloxetine. * **Urge Incontinence:** Characterized by a sudden, intense urge to void. Treatment focuses on anticholinergics [1].

Q: Which drug is contraindicated in bilateral renal artery stenosis?

Captopril. **Explanation:** The correct answer is **Captopril (Option C)**. **Why Captopril is the correct answer:** In patients with **bilateral renal artery stenosis (RAS)**, the perfusion pressure to the kidneys is significantly reduced. To maintain an adequate Glomerular Filtration Rate (GFR), the body relies on the **Renin-Angiotensin-Aldosterone System (RAAS)**. Specifically, Angiotensin II causes **vasoconstriction of the efferent arteriole**, which creates the necessary back-pressure to maintain filtration. Captopril, an ACE inhibitor, prevents the formation of Angiotensin II. This leads to efferent arteriolar vasodilation, a sudden drop in intraglomerular pressure, and subsequent **acute renal failure**. Therefore, ACE inhibitors (and ARBs) are strictly contraindicated in bilateral RAS or RAS in a solitary functioning kidney. **Analysis of Incorrect Options:** * **A. Propranolol:** A non-selective beta-blocker. While it reduces renin release, it does not cause the acute hemodynamic collapse of GFR seen with ACE inhibitors. * **B. Guanethidine:** An older adrenergic neuron blocker. It lowers blood pressure by inhibiting norepinephrine release but does not specifically target the renal autoregulatory mechanism. * **D. Amlodipine:** A Calcium Channel Blocker (CCB). CCBs primarily dilate the *afferent* arteriole and are generally considered safe (and often preferred) in patients with renal artery stenosis. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnostic Clue:** Suspect bilateral RAS if a patient’s serum creatinine rises by **>30%** after starting an ACE inhibitor or ARB. * **Drug of Choice:** CCBs or Beta-blockers are safer alternatives for hypertension in bilateral RAS. * **Teratogenicity:** ACE inhibitors are also contraindicated in pregnancy (Category X) due to fetal renal dysgenesis and skull hypoplasia.

Q: Triflusal is a:

Antiplatelet drug. **Explanation:** **Triflusal** is a fluorinated salicylate derivative that acts as a potent **antiplatelet drug**. While it is structurally related to acetylsalicylic acid (Aspirin), its pharmacological profile is distinct. **Why Option D is correct:** Triflusal exerts its antiplatelet effect through two primary mechanisms: 1. **Irreversible inhibition of Cyclooxygenase-1 (COX-1):** This prevents the synthesis of Thromboxane A2 (TXA2), a potent platelet aggregator. 2. **Inhibition of Phosphodiesterase (PDE):** Unlike Aspirin, Triflusal inhibits the enzyme phosphodiesterase, leading to increased levels of cyclic AMP (cAMP) in platelets. This further inhibits platelet activation and promotes vasodilation. Crucially, at therapeutic doses, Triflusal spares the synthesis of **Prostacyclin (PGI2)** in vascular endothelial cells, maintaining a favorable antithrombotic balance with a lower risk of bleeding compared to Aspirin. **Why other options are incorrect:** * **A & C (Anti-inflammatory/Anti-arthritic):** Although it is a salicylate, Triflusal is not used clinically for its anti-inflammatory or analgesic properties. Its use is strictly restricted to the prevention of thromboembolic events. * **B (Antibiotic):** Triflusal has no antimicrobial activity and does not target bacterial structures or protein synthesis. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Used for secondary prevention of stroke, myocardial infarction, and unstable angina. * **Active Metabolite:** It is metabolized into **HTB** (2-hydroxy-4-trifluoromethylbenzoic acid), which also possesses antiplatelet activity and has a long half-life (approx. 35 hours). * **Safety Profile:** It is associated with a significantly **lower incidence of gastrointestinal complications** and hemorrhagic events compared to Aspirin, making it a preferred alternative in high-risk patients.

Q: Which of the following is NOT true about fibrates?

Absorption is delayed by a fatty meal. **Explanation:** Fibrates (e.g., Gemfibrozil, Fenofibrate) are a class of lipid-lowering agents primarily used to target high triglyceride levels. **1. Why Option C is the correct (False) statement:** Contrary to the statement, the absorption of most fibrates is actually **enhanced**, not delayed, by a fatty meal. Fenofibrate, in particular, shows significantly improved bioavailability when taken with food. This is a high-yield pharmacological detail often tested to differentiate it from other drugs where food might impair absorption. **2. Analysis of other options:** * **Option A (True):** Fibrates are the **Drug of Choice (DOC)** for **Type III Hyperlipoproteinemia** (Dysbetalipoproteinemia) and **Severe Hypertriglyceridemia** (TG >500 mg/dL) to prevent acute pancreatitis. * **Option B (True):** Their primary mechanism involves activating **PPAR-alpha** (Peroxisome Proliferator-Activated Receptor-alpha). This leads to increased expression of **Lipoprotein Lipase (LPL)**, which enhances the catabolism of VLDL and triglycerides. * **Option D (True):** Common side effects include GI upset, skin rashes, urticaria, and myalgia. **Impotence** is a documented, though less common, side effect of clofibrate and other members of this class. **Clinical Pearls for NEET-PG:** * **Risk of Myopathy:** The risk of rhabdomyolysis increases significantly when fibrates (especially Gemfibrozil) are combined with **Statins**, as gemfibrozil inhibits the glucuronidation of statins, increasing their plasma levels. * **Gallstones:** Fibrates increase biliary cholesterol excretion, leading to a higher risk of **cholelithiasis** (gallstones). * **Contraindications:** Avoid in patients with severe hepatic or renal dysfunction and gallbladder disease.

Q: Which of the following is an indication for the use of eptifibatide?

Angina. **Explanation:** **Eptifibatide** is a potent **Glycoprotein (GP) IIb/IIIa receptor antagonist**. It works by reversibly inhibiting the final common pathway of platelet aggregation—the binding of fibrinogen to the GP IIb/IIIa receptors on activated platelets. **Why Angina is Correct:** Eptifibatide is primarily indicated for the management of **Acute Coronary Syndromes (ACS)**, which includes **Unstable Angina** and Non-ST-elevation myocardial infarction (NSTEMI). It is also used in patients undergoing Percutaneous Coronary Intervention (PCI) to prevent thrombotic complications. By preventing platelet thrombus formation, it maintains coronary artery patency and reduces the risk of ischemic events. **Why Other Options are Incorrect:** * **HIV:** This is a viral infection treated with Antiretroviral Therapy (ART), such as Protease Inhibitors or Reverse Transcriptase Inhibitors. Eptifibatide has no antiviral properties. * **Congestive Cardiac Failure (CCF):** CCF is managed with diuretics, ACE inhibitors, beta-blockers, and inotropes. While ACS can lead to CCF, eptifibatide is not a treatment for the heart failure state itself. * **Hypertension:** Hypertension is managed with antihypertensives like CCBs, ACE inhibitors, or Thiazides. Eptifibatide does not lower blood pressure. **NEET-PG High-Yield Pearls:** * **Mechanism:** It is a cyclic heptapeptide derived from rattlesnake venom (Sistrurus miliarius barbouri). * **Classmates:** Other GP IIb/IIIa inhibitors include **Abciximab** (monoclonal antibody - irreversible) and **Tirofiban** (non-peptide - reversible). * **Route:** Administered only via the **intravenous** route. * **Side Effect:** The most significant adverse effect is **bleeding** and occasionally thrombocytopenia. * **Excretion:** It is primarily cleared by the kidneys; dose adjustment is required in renal impairment.

Question 1

Which of the following is not a first-line antihypertensive medication?

Accepted Answer

Atenolol

Answer

Enalapril

Answer

Hydrochlorothiazide

Answer

Amlodipine

Question 2

Ivabradine is used for the management of which condition?

Accepted Answer

Stable angina

Answer

Pre-renal azotemia

Answer

Alzheimer's disease

Answer

Smoking cessation

Question 3

All of the following drugs are useful in detrusor instability except?

Accepted Answer

Duloxetine

Answer

Solefenacin

Answer

Tolterodine

Answer

Flavoxate

Question 4

Which drug is contraindicated in bilateral renal artery stenosis?

Accepted Answer

Captopril

Answer

Propranolol

Answer

Guanethidine

Answer

Amlodipine

Question 5

Sudden withdrawal of which of the following drugs could result in serious adverse cardiovascular changes in a patient taking the drug over a long time?

Accepted Answer

Clonidine (α2 agonist)

Answer

Phenelzine (MAO inhibitor)

Answer

Enalapril (ACE inhibitor)

Answer

Fluoxetine (serotonin reuptake inhibitor)

Question 6

What is the biochemical mechanism of action of digitalis?

Accepted Answer

An increase in systolic intracellular calcium levels

Answer

An increase in conduction from the atria to the ventricle

Answer

An increase in ATP synthesis

Answer

A block of calcium channels

Question 7

Triflusal is a:

Accepted Answer

Antiplatelet drug

Answer

Anti-inflammatory drug

Answer

Antibiotic

Answer

Anti-arthritic drug

Question 8

Which of the following is NOT true about fibrates?

Accepted Answer

Absorption is delayed by a fatty meal

Answer

Drug of choice for type III hyperlipoproteinemia and severe hypertriglyceridemia

Answer

Activate PPAR-alpha to stimulate LPL

Answer

Side effects include rash, urticaria, myalgia, and impotence

Question 9

Enalapril increases the levels of which of the following?

Accepted Answer

Bradykynin

Answer

Interferon

Answer

Platelet-activating factor (PAF)

Answer

Tumor necrosis factor (TNF)

Question 10

Which of the following is an indication for the use of eptifibatide?

Accepted Answer

Angina

Answer

HIV

Answer

Congestive Cardiac Failure

Answer

Hypertension

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?